Proactive Investors - Run By Investors For Investors

Proactive Investors One2One Investor Forum - London

Abzena plc | Scancell Holdings Plc | Kin Group Plc | ReNeuron Group Plc

The presentations will start at 6:00pm and finish at approx 8:00pm. After the presentations are complete the directors will also be available to take questions during a free canapé and wine reception. Details on the presenting companies can be found below.


This event is suitable for the following:

Sophisticated & private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.


The event is not suitable for people pursuing commercial opportunities.


Abzena plc

RSS Portfolio


Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.

The term "Abzena inside" is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ antibody drug conjugates. Abzena has the potential to earn future licence fees, milestone payments and/or royalties on "Abzena inside" products.


Market: AIM
52-week High/Low: 66.00p / 31.00p
Market Cap: 96.12M

View full company profile

Kin Group Plc

RSS Portfolio


Kin is a dynamic, global wellness tech company, providing digital wellness solutions that empower employers to create a positive culture of wellness within their organizations. By helping employees to embrace a healthier way of living, Kin can help to maximize performance, reduce absenteeism, decrease the risk of chronic illness and lower healthcare costs.

Our technological edge allows us to address holistic well-being by engaging both individuals and teams through intelligent, personalized interaction and gamification. This is an opportunity to make incremental behavioral changes that will last a lifetime. The progress of individuals then translates to actionable data, meaningful reporting and insights that allow the organization to monitor the impact of the program and to refine it in order to achieve success.

Market: AIM
52-week High/Low: 1.09p / 0.08p
Market Cap: 1.42M

View full company profile

ReNeuron Group Plc

RSS Portfolio


ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron is traded in the ISDX Exchange HERE

Market: AIM
52-week High/Low: 3.68p / 1.76p
Market Cap: 58.55M

View full company profile

Scancell Holdings Plc

RSS Portfolio


Cancer remains one of the world’s most significant diseases. A key challenge in the fight against cancer is that many tumours continue to grow by successfully evading the body’s own natural defence mechanism - the immune system. Scancell’s mission is to overcome this breach in our defences by developing products that stimulate the immune system to treat or prevent cancer.

Scancell is traded in the ISDX Exchange HERE

Market: AIM
52-week High/Low: 19.70p / 9.68p
Market Cap: 31.60M

View full company profile

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use